Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.

Consistent with previous findings, there was a trend toward increased incidence of brain metastases in patients whose tumors had deleterious mutations in STK 11 ( figure 4A ) and KEAP1 ( figure 4B ); however, this did not reach statistical significance. 17 Because STK11 and KEAP1 are both located on chromosome 19p and are commonly codeleted, we sought to determine whether copy number of these genes pretreatment is also associated with brain-recurrent disease as in previous studies. 17 STK11 copy number was significantly lower pretreatment in patients with brain metastases ( figure 4C ); this trend was not observed with KEAP1 copy number ( figure 4D ).

also in 111,027 other papers